Grifols SA
Company Profile
Business description
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.
Contact
Avinguda de la Generalitat, 152-158
Parc de Negocis Can Sant Joan
Sant Cugat del Valles
Barcelona08174
ESPT: +34 935710500
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
23,822
Stocks News & Analysis
stocks
6 undervalued stocks with low beta
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,772.00 | 1.00 | -0.01% |
CAC 40 | 7,637.74 | 28.17 | -0.37% |
DAX 40 | 23,800.13 | 109.48 | -0.46% |
Dow JONES (US) | 44,094.77 | 275.50 | 0.63% |
FTSE 100 | 8,735.30 | 25.66 | -0.29% |
HKSE | 24,072.28 | 211.87 | -0.87% |
NASDAQ | 20,369.73 | 96.27 | 0.47% |
Nikkei 225 | 39,986.33 | 501.06 | -1.24% |
NZX 50 Index | 12,734.53 | 131.71 | 1.05% |
S&P 500 | 6,204.95 | 31.88 | 0.52% |
S&P/ASX 200 | 8,541.10 | 1.20 | -0.01% |
SSE Composite Index | 3,444.43 | 20.20 | 0.59% |